Cinque Felice, Long Clara, Dinh Duy A, Gore Genevieve, Swain Mark, Ramji Alnoor, Patel Keyur, Betel Michael, Bajaj Harpreet S, Dasgupta Kaberi, Poder Thomas G, Saeed Sahar, Sebastiani Giada
Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada.
Division of Gastroenterology & Hepatology, McGill University Health Centre, Montreal, Quebec, Canada.
Can Liver J. 2025 Feb 25;8(1):63-78. doi: 10.3138/canlivj-2024-0050. eCollection 2025 Feb.
We aimed to summarize the evidence on the use of discrete choice experiments (DCEs) and conjoint analyses to quantify stakeholders' preferences for screening programs for type 2 diabetes (T2D) and liver diseases, with a specific focus on metabolic dysfunction-associated steatotic liver disease (MASLD).
For this scoping review, five databases (MEDLINE [PubMed], PubMed Central, EMBASE [Ovid], Europe PMC, Google Scholar) were searched with the assistance of a librarian, and deduplicated records were screened by two independent reviewers. Inclusion criteria: using DCE/CA, addressing screening programs for T2D and liver disease, published in English, French, or Spanish after January 1990.
Among 2,282 studies, 9 (7 from high- and 2 from low-income countries) elicited preferences for screening for liver disease (n = 1), hepatitis C (n = 1), hepatitis B (n = 1), hepatocellular carcinoma (n = 2), noncommunicable diseases (n = 2), diabetic retinopathy (n = 1), and cardiovascular diseases (n = 1). No studies addressed MASLD screening in T2D. Stakeholders included patients (n = 3), health care providers (n = 1), patients plus health care providers (n = 1), and the general population (n = 3). Studies used 18 structure, 6 process, and 4 outcome attributes. Screening sensitivity, setting, duration, provider, and cost were the most important structure attributes in participant choices. Physician support for treatment was the preferred process attribute. Outcome attributes were the least used, but of major importance (screening adherence followed by treatment) when considered.
With no study focusing on MASLD screening in T2D, our scoping review highlights the need to develop a DCE addressing this topic to better design a patient-centred continuum of care.
我们旨在总结关于使用离散选择实验（DCE）和联合分析来量化利益相关者对2型糖尿病（T2D）和肝脏疾病筛查项目偏好的证据，特别关注代谢功能障碍相关脂肪性肝病（MASLD）。
对于这项范围综述，在一名图书馆员的协助下检索了五个数据库（MEDLINE [PubMed]、PubMed Central、EMBASE [Ovid]、Europe PMC、谷歌学术），由两名独立评审员筛选去重后的记录。纳入标准：使用DCE/CA，涉及T2D和肝脏疾病的筛查项目，1990年1月后以英文、法文或西班牙文发表。
在2282项研究中，9项（7项来自高收入国家，2项来自低收入国家）得出了对肝脏疾病（n = 1）、丙型肝炎（n = 1）、乙型肝炎（n = 1）、肝细胞癌（n = 2）、非传染性疾病（n = 2）、糖尿病视网膜病变（n = 1）和心血管疾病（n = 1）筛查的偏好。没有研究涉及T2D中的MASLD筛查。利益相关者包括患者（n = 3）、医疗保健提供者（n = 1）、患者加医疗保健提供者（n = 1）和普通人群（n = 3）。研究使用了18个结构属性、6个过程属性和4个结果属性。筛查敏感性、地点、持续时间、提供者和成本是参与者选择中最重要的结构属性。医生对治疗的支持是首选的过程属性。结果属性使用最少，但在考虑时至关重要（筛查依从性其次是治疗）。
由于没有研究关注T2D中的MASLD筛查，我们的范围综述强调需要开展一项针对该主题的DCE，以更好地设计以患者为中心的连续护理。
